Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
JR Ussher, DJ Drucker - Nature Reviews Cardiology, 2023 - nature.com
Type 2 diabetes mellitus (T2DM) and obesity are metabolic disorders characterized by
excess cardiovascular risk. Glucagon-like peptide 1 (GLP1) receptor (GLP1R) agonists …
excess cardiovascular risk. Glucagon-like peptide 1 (GLP1) receptor (GLP1R) agonists …
COVID-19 and diabetes mellitus: from pathophysiology to clinical management
Initial studies found increased severity of coronavirus disease 2019 (COVID-19), caused by
infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in patients …
infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in patients …
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
R Hammoud, DJ Drucker - Nature Reviews Endocrinology, 2023 - nature.com
Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP1)
exhibit incretin activity, meaning that they potentiate glucose-dependent insulin secretion …
exhibit incretin activity, meaning that they potentiate glucose-dependent insulin secretion …
[HTML][HTML] GLP-1 physiology informs the pharmacotherapy of obesity
DJ Drucker - Molecular metabolism, 2022 - Elsevier
Background Glucagon-like peptide-1 receptor agonists (GLP1RA) augment glucose-
dependent insulin release and reduce glucagon secretion and gastric emptying, enabling …
dependent insulin release and reduce glucagon secretion and gastric emptying, enabling …
Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) exert anti-inflammatory effects
relevant to the chronic complications of type 2 diabetes. Although GLP-1RAs attenuate T cell …
relevant to the chronic complications of type 2 diabetes. Although GLP-1RAs attenuate T cell …
The expanding incretin universe: from basic biology to clinical translation
DJ Drucker, JJ Holst - Diabetologia, 2023 - Springer
Incretin hormones, principally glucose-dependent insulinotropic polypeptide (GIP) and
glucagon-like peptide-1 (GLP-1), potentiate meal-stimulated insulin secretion through direct …
glucagon-like peptide-1 (GLP-1), potentiate meal-stimulated insulin secretion through direct …
Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications
Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including empagliflozin, dapagliflozin,
and canagliflozin, are now widely approved antihyperglycemic therapies. Because of their …
and canagliflozin, are now widely approved antihyperglycemic therapies. Because of their …
The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE−/− and LDLr−/− Mice by a Mechanism That Includes Inflammatory Pathways
G Rakipovski, B Rolin, J Nøhr, I Klewe… - JACC: Basic to …, 2018 - jacc.org
The glucagon-like peptide-1 receptor agonists (GLP-1RAs) liraglutide and semaglutide
reduce cardiovascular risk in type 2 diabetes patients. The mode of action is suggested to …
reduce cardiovascular risk in type 2 diabetes patients. The mode of action is suggested to …
The cardiovascular biology of glucagon-like peptide-1
DJ Drucker - Cell metabolism, 2016 - cell.com
Glucagon-like peptide-1, produced predominantly in enteroendocrine cells, controls glucose
metabolism and energy homeostasis through regulation of islet hormone secretion …
metabolism and energy homeostasis through regulation of islet hormone secretion …
The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction
C Withaar, LMG Meems… - Cardiovascular …, 2021 - academic.oup.com
Aims Heart failure with preserved ejection fraction (HFpEF) is a multifactorial disease that
constitutes several distinct phenotypes, including a common cardiometabolic phenotype …
constitutes several distinct phenotypes, including a common cardiometabolic phenotype …